1369594-41-1

Basic information

• Product Name: 1 - (4 - broMo-2 - fluoro-6 - hydroxyphenyl) ethanone
• Synonyms: 1 - (4 - broMo-2 - fluoro-6 - hydroxyphenyl) ethanone;4-BroMo-2-fluoro-6-hydroxyacetophenone;1-(4-bromo-2-fluoro-6-hydroxyphenyl)ethan-1-one;1-(4-bromo-2-fluoro-6-hydroxyphenyl)ethanone(WXFC0237)
• CAS NO: 1369594-41-1
• Molecular Formula: C₈H₆BrFO₂
• Molecular Weight: 233.0344432
• Mol File: 1369594-41-1.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 288.2±40.0 °C(Predicted)
• Appearance: /
• Density: 1.667±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 8.20±0.15(Predicted)
• CAS DataBase Reference: 1 - (4 - broMo-2 - fluoro-6 - hydroxyphenyl) ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1 - (4 - broMo-2 - fluoro-6 - hydroxyphenyl) ethanone(1369594-41-1)
• EPA Substance Registry System: 1 - (4 - broMo-2 - fluoro-6 - hydroxyphenyl) ethanone(1369594-41-1)

Safety Data

• Hazardous Substances Data: 1369594-41-1(Hazardous Substances Data)

Usage

General Description

1 - (4 - bromo-2 - fluoro-6 - hydroxyphenyl) ethanone is a chemical compound with the molecular formula C8H7BrFO2. It is a derivative of acetophenone, containing a bromo and fluoro group, as well as a hydroxy group on the phenyl ring. 1 - (4 - broMo-2 - fluoro-6 - hydroxyphenyl) ethanone is commonly used in organic synthesis and pharmaceutical research as a building block for the synthesis of various biologically active compounds. It has also been studied for its potential pharmacological properties, including anti-inflammatory, analgesic, and anti-cancer activities. Additionally, it may have potential applications in the development of new drugs and agrochemicals.

Upstream product

• 1260846-67-0 3-bromo-5-fluorophenyl acetate 
• 141-78-6 ethyl acetate 

Downstream Products

• 1369594-45-5 C₁₄H₈Br₂FNO 
• 1370468-13-5 C₁₄H₈BrClFNO 
• 1620450-59-0 C₁₄H₁₀BrClFNO 
• 1620545-75-6 3,10-dibromo-6-(2-cyclopropyl-1,3-thiazol-5-yl)-1-fluoro-6H-indolo[1,2-c][1,3]benzoxazine 
• 1613081-64-3 dimethyl((2S,2’S)-((2S,2’S)-2,2’-(5,5’-((S)-6-(2-cyclopropylthiazol-5-yl)-1-fluoro-6H-benzo[5,6][1,3]oxazino[3,4-a]indole-3,10-diyl)bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3methyl-1oxobutane-2,1-diyl))dicarbamate 
• 1620450-58-9 5-bromo-2-(5-bromoindolin-2-yl)-3-fluorophenol 
• 1369594-44-4 C₁₄H₁₁Br₂FN₂O 

Relevant articles and documents

Spiro derivative, preparation method thereof and application of spiro derivative in medicine

The invention relates to a spiro derivative, a preparation method thereof and application of the spiro derivative in medicine. Specifically, the invention relates to the spiro derivative shown in a general formula (I), the preparation method thereof, a pharmaceutical composition containing the spiro derivative and application of the spiro derivative as a therapeutic agent, especially application of the spiro derivative as an RAF inhibitor and application of the spiro derivative in preparation of drugs for treating or preventing various diseases (including cancers) related to over-expression RAF activity.

Substituted tetracyclic indole core derivatives of HCV NS5A inhibitor MK-8742

As part of an ongoing effort in NS5A inhibition at Merck we now describe our efforts for introducing substitution around the tetracyclic indole core of MK-8742. Fluoro substitution on the core combined with the fluoro substitutions on the proline ring improved the potency against GT1a Y93H significantly. However, no improvement on GT2b potency was achieved. Limiting the fluoro substitution to C-1 of the tetracyclic indole core had a positive impact on the potency against the resistance associated variants, such as GT1a Y93H and GT2b, and the PK profile as well. Compounds, such as 62, with reduced potency shifts between wild type GT1a to GT2b, GT1a Y93H, and GT1a L31V were identified.

TETRACYCLIC INDOLE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION

Tetracyclic indole derivatives of formula (I), pharmaceutically acceptable salts and the pharmaceutical compositions thereof are provided, wherein A, A', G, R1, R15, U, V, V, W, W, X, X', Y, Y' are as defined in the invention. Use of these derivatives for treating hepatitis C virus (HCV) infection is also provided.